Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms, drawn from the whole corpus: 1 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
2 medicines on record are linked to one of the types below rather than to Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms itself. Grouped by the type that holds them; each list opens that type's own page.
Most patients relapse when BRAF or MEK inhibitors stop; intermittent dosing and ctDNA-guided discontinuation are being tested.
Nothing recorded yet.
Nothing recorded yet.
Background: Circulating tumour DNA (ctDNA). Also on OnCo: Treatment journeys · Survivorship planner.
Neurodegenerative ECD and LCH do not reverse with targeted therapy; earlier treatment and neuroprotective trials are the response.
Histiocytic sarcoma remains aggressive; MAPK inhibitors and immunotherapy are being tried.
Rarity: the Histiocyte Society, the ECD Global Alliance registry and NCCN's 2021 guideline coordinate what evidence exists.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Find a trial · Expert centres.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 11 changes by month →When this page itself was last checked or edited.
FDA approval October 2022 for adults with ECD, RDD and LCH.
Vemurafenib (FDA approval 2017) or dabrafenib, often with a MEK inhibitor to reduce toxicity; long-term treatment at the lowest effective dose.
Diamond and colleagues, Nature Medicine 2019.
Observation for asymptomatic nodal disease; surgery for isolated masses; steroids, sirolimus, cladribine or MEK inhibitors for symptomatic or multifocal disease.
Erdheim-Chester disease with BRAF V600 mutation